On Thursday, Drug maker Lupin informed that it had inked a licensing pact with Japan-based I’rom Group Co for a product used, inter alia, in treating postmenopausal women with osteoporosis. As per the agreement, I’rom and Lupin are to conduct clinical trials, register, distribute and market biosimilars Denosumab in Japan on an exclusive basis.

Denosumab, a human monoclonal antibody, is indicated for the treatment of osteoporosis in postmenopausal women at high risk of fracture. It also prevents skeletal-related events in patients with bone metastases from solid tumours. Denosumab is currently available under two brands- Pralia and Ranmark. It has a market size of about USD 500 million in Japan.

Lupin’s Managing Director said that Biosimilars are a key growth driver for Lupin. Through products like Denosumab, the company is making significant progress in improving access and affordability of crucial treatments for patients.
Lupin President Biotechnology Cyrus Karkaria said estrogen decline primarily causes osteoporosis in postmenopausal women. It can result in severe clinical consequences, including back pain and bone fractures.

Headquartered in Mumbai, Lupin Limited was founded by Desh Bandhu Gupta in 1968. It has become one of the largest generic pharmaceutical companies by revenue globally. Its focus areas include paediatrics, cardiovascular, asthma and anti-tuberculosis. After this news, shares of Lupin were trading 1.2% down at Rs 669.50 apiece on the BSE.